I am happy to say I have been accepted on the MolMed trial at Maidstone Hospital.
‘MolMed expands NGR-hTNF trial in US’
PBR Staff Writer Published 26 October 2011
MolMed, a biotechnology company, has expanded the Phase III trial of its investigational anticancer drug NGR-hTNF in malignant pleural mesothelioma, in the US.
NGR-hTNF is a vascular targeting agent belonging to peptide/cytokine complexes, which can selectively target the tumour vasculature.
The randomised, double-blind, placebo-controlled, multicentre Phase III NGR015 trial, will enroll 390 adult patients affected by malignant pleural mesothelioma with disease progressing after standard pemetrexed-based chemotherapy.
The primary endpoint is overall survival, while the secondary endpoints include progression-free survival, disease control rate, safety and patients' quality of life.
The company expects to announce the results in 2013.’
There is a 50:50 chance I will get the drug or the placebo – but that is the chance I will have to take and with the backup of chemo it really is my best option. It will be a difficult journey – 2 hospital visits each week, consultant every third week, scan every 6 weeks, chemo day 1 and 8 of a 21 day cycle....... It is an hours drive each way to Maidstone so long days ahead. Whatever the outcome for me the info gained by the research team will hopefully benefit the next generation of asbestos harmed people.
This regime will all start next Thursday Nov 10th so wish me and Alan luck as we take this step into the unknown – scarey but with uncertainty comes hope.